At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 560 enrolled
Drug / intervention
risankizumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
In Brief
A Phase 3 clinical trial evaluating risankizumab, placebo for risankizumab, and 2 other interventions for Psoriasis. Completed, enrolled 560 participants.
Detailed Summary
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsBoehringer Ingelheim
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedFeb 2016
Primary CompletionDec 2016
Study CompletionSep 2017
TodayJul 2026
First PostedFeb 18, 2016
Enrollment StartFeb 1, 2016
Primary CompletionDec 1, 2016
Study CompletionSep 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 10.4 years ago
Interventions
risankizumabdrug
Risankizumab administered by subcutaneous (SC) injection
placebo for risankizumabdrug
Placebo for risankizumab administered by subcutaneous (SC) injection
ustekinumabdrug
Ustekinumab administered by subcutaneous (SC) injection
placebo for ustekinumabdrug
Placebo for ustekinumab administered by subcutaneous (SC) injection